A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

NCT07234591

Status	RECRUITING
Phase	Not Applicable
Sponsor	Usynova Pharmaceuticals Ltd.
Enrollment	140 participants

Key Eligibility Criteria

Inclusion (4)

- Male and female, ages 18 to 70 years
- Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
- Clinical diagnosis of plaque psoriasis for e6 months before the Baseline visit
- Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.

Exclusion (7)

- Diagnosed with non-plaque psoriasis
- Previously received tyrosine kinase 2 (TYK2) inhibitors
- Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects
- Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
- Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.

... and 2 more (see full listing online)

Locations (1 total)

Shanghai Skin Disease Hospital, Shanghai, China